Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Recruiting now · Phase 2
Conditions studied: Extensive-Stage Small Cell Lung Cancer
In brief
This is a single-arm, open-lable exploratory study of Lurbinectedin in combination with Serplulimab as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and Serplulimab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and Serplulimab induction treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will receive lurbinectedin plus Serplulimab in the maintenance phase.
Key facts
- Study ID
- NCT06497530
- Run by
- Guangzhou Institute of Respiratory Disease
- People needed
- 30
- Starts
- 2024-12-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-06-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The first affiliated hospital of Guangzhou medical university — Guangzhou, Guangdong, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.